Open AccessAbstract CT269: A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007
Author(s) -
Timothy A. Yap,
Mallika Sachdev Dhawan,
Andrew Eugene Hendifar,
Michele Maio,
Taofeek K. Owonikoko,
Miguel Quintela-Fandiño,
Ronnie ShapiraFrommer,
Sanatan Saraf,
Ping Qiu,
Fan Jin,
Alexander Gozman,
Douglas A. Levine
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct269
Subject(s) - olaparib , medicine , pembrolizumab , parp inhibitor , ovarian cancer , oncology , cancer , brca mutation , cancer research , pancreatic cancer , breast cancer , immunotherapy , poly adp ribose polymerase , polymerase , biology , gene , biochemistry